Massive study aims to unlock secrets of childhood nerve and muscle diseases
NCT ID NCT01568658
First seen Jun 24, 2026 · Last updated Sep 10, 2026 · Updated 5 times
Summary
This long-term study looks at children and adults with inherited nerve and muscle disorders that start early in life, like muscular dystrophy. Researchers will track symptoms over time and collect genetic samples from affected individuals, their family members, and healthy volunteers. The goal is to better understand these conditions and develop tools for future clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify better ways to measure disease progression and find genetic causes, helping design future treatments.
- What could go wrong
- This is an observational study, not testing a treatment. It may not directly lead to new therapies, and results depend on long-term participation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
2,586 people
The number who actually took part.
- Started
-
Mar 2012
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Affected probands with the following categories of childhood onset inherited neurological disorders will be enrolled:-peripheral neuropathies; -muscular dystrophies and myopathies; -congenital muscular dystrophies and congenital myopathies; -disorders of the neuromuscular junction; -motor neuron disorders; -neuromotor or movement disorders; -disorders of brain development; -neurometabolic disorders; -disorders that have a phenotype suggestive of neurogenetic or neuromuscular disease but which have not yet been genetically confirmed. Families of affected probands, with known or suspected inherited neurological disorders of childhood onset will be enrolled. Healthy volunteers will enrolled for one-time imaging procedures. A single patient with compound heterozygous FDX2 mutations will be enrolled under an emergency IND for use of Idebenone for slowing progression of subacute blindness.
- Ages
-
1 day to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION AND EXCLUSION CRITERIA: Probands inclusion criteria Phase 1: 1. Aged 4 weeks and older 2. Documentation of a personal history of a childhood-onset, hereditary/familial, neurological disorder or later onset of a disease that more commonly has childhood onset. Acceptable documentation includes evaluation through any or all of the following evaluations done prior to enrollment. 1. Medical history, including family history information 2. Physical examination 3. Muscle, nerve, or skin biopsy 4. Magnetic resonance imaging (MRI) 5. Electromyography (EMG) 6. Nerve conduction study (NCS) 7. Electroencephalogram (EEG) 8. Muscle ultrasound 9. Genetic, metabolic, or other laboratory testing such as increased serum Creatine Kinase (CK) and abnormal serum lactate/pyruvate ratio. Exclusion criteria for probands Phase 1: 1. Individuals who are unable or unwilling to be examined 2. Minors who do not hve a parent or guardian able to provide informed consent 3. Adults seen offsite who are unable to provide their own consent Probands inclusion criteria Phase 2: 1. Aged 4 weeks and older 2. Documentation of a defined childhood onset neuromuscular and neurogenetic disorders through phase 1 testing. Exclusion criteria for probands Phase 2: 1. Individuals who are unable or unwilling to be examined. 2. Adults who are unable to provide their own consent and who have not previously appointed an individual with Durable Power of Attorney (DPA) or who are unable to appoint a DPA or guardian. 3. Minors who do not have a parent or guardian able to provide informed consent. 4. Adults seen offsite who are unable to provide their own consent. Unaffected Family members - Inclusion Criteria: 1. Unaffected family members must be related by blood to a proband enrolled in the study. Biological relations may include first (parent or sibling), second (grandparents, aunts, uncles, half siblings) and third degree relatives (cousins). 2. Age 4 weeks and older. Unaffected Family members - Exclusion Criteria: 1. Individuals whom are unable or unwilling to be examined. 2. Family members who are showing symptoms of the familial neurogenetic or neuromuscular condition (these may be enrolled as probands). 3. Neonates. 4. Adults who are unable to provide their own consent. Healthy Volunteers - Inclusion Criteria: 1. Must be unaffected by a neurological condition. 2. Willing and able to comply with all protocol requirements and procedures, including MRI without sedation and without contrast. 3. Able to give informed assent and parent(s)/legal guardian to give informed consent in writing signed by the subject and/or parent(s)/legal guardian. Healthy Volunteers - Exclusion Criteria: 1. Healthy volunteers who have metal objects in their body that are not MRI-safe. These include the following objects: 1) pacemakers or other implanted electrical devices; 2) brain stimulators; 3) some types of dental implants; 4) aneurysm clips (metal clips on the wall of a large artery); 5) metallic prostheses (including metal pins and rods, heart valves, and cochlear implants; 6) implanted delivery pump; 7) permanent eye liner; or 8) shrapnel fragments. 2. Healthy volunteers who have a fear of closed spaces. 3. Neonates. 4. Pregnant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hereditary spastic paraplegias are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a brain implant let paralyzed people control computers with their minds?
- Tissue donations could unlock secrets of muscle diseases
- New study aims to sharpen tools for tracking becker muscular dystrophy
- New drug could help boys with duchenne walk and move longer
- New hope for FSHD: Long-Term drug safety trial underway
- Hope for duchenne: new drug targets rare gene mutation in phase 3 trial